Thermo Fisher Scientific in the news
Serving science for innovation
Tamtam found 18 recent articles about Thermo Fisher Scientific.
- Client Wins Could Be A Game Changer For Thermo Fisher Stock
Thermo Fisher Scientific recently secured a new clinical trial, launched new drug development solutions, and expanded its offerings, signaling a strategic shift towards outsourced drug development and data-driven clinical services.
- What Could Thermo Fisher Scientific (TMO) Change With Its New Digital CMC Consortium?
Thermo Fisher Scientific co-launched the Digital CMC Consortium to advance digital Chemistry, Manufacturing, and Controls in biopharma by establishing shared digital standards.
- Ex-Thermo Fisher Manager Blames Age, Sex Bias For Ouster
An ex-Thermo Fisher Scientific manager accuses the company of age and sex bias leading to his ouster.
- Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $678.17, Implies 2% Upside
Thermo Fisher Scientific Inc.'s average stock price target was raised to $678.17, indicating a 2% upside.
- Thermo Fisher Scientific Inc. stock falls Thursday, underperforms market
Thermo Fisher Scientific Inc. stock declined on Thursday, underperforming the market.
- Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight
Thermo Fisher Scientific's clinical research unit partnered with Quantum BioPharma to initiate a Phase 2 multiple sclerosis trial, while the company's stock shows strong market momentum but is considered slightly overvalued.
- Quantum BioPharma (QNTM) Engages Thermo Fisher Unit for Phase 2 Lucid-MS Trial
Quantum BioPharma partnered with Thermo Fisher Scientific's clinical research unit for the Phase 2 trial of its multiple sclerosis drug candidate, Lucid-MS.
- Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan
Thermo Fisher Scientific is presenting new and expanded drug development, manufacturing, and packaging solutions at CPHI Milan.
- Thermo Fisher Scientific (TMO) Wins New Biopharma Work, Is The Stock Already Fully Valued?
Thermo Fisher Scientific won new biopharma contracts, driving strong stock performance and a slight overvaluation according to analysts, amidst expectations of continued growth from the pharma and biotech sectors.
- Barclays Adjusts Thermo Fisher Scientific Price Target to $750 From $650, Maintains Overweight Rating
Barclays has raised its price target for Thermo Fisher Scientific to $750 from $650 while maintaining an Overweight rating.
- Thermo Fisher Scientific Launches Thermo Scientific™ Nicolet™ RaptIR™ X FTIR Microscope, Bringing Speed and Simplicity to Advanced Infrared Analysis
Thermo Fisher Scientific introduces the Nicolet RaptIR X FTIR Microscope to make chemical analysis of microscopic samples more accessible, intuitive, and efficient for laboratories.
- Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Quantum BioPharma signed a contract with Thermo Fisher Scientific's clinical research business for a Phase 2 Lucid-MS trial in multiple sclerosis patients.
- Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific
The Medical Instruments industry is embracing Generative AI for accelerated drug development and diagnostics, navigating evolving regulations, and experiencing significant M&A activity.
- Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
ClearBridge Large Cap Growth Strategy's Q3 2026 letter noted Thermo Fisher Scientific Inc. as a positive contributor due to strong earnings and optimistic guidance.
- Thermo Fisher Scientific Announces Launch of New FT-IR Microscope for Microscale Chemical Analysis
Thermo Fisher Scientific introduced the Nicolet RaptIR X FTIR Microscope, a new instrument combining optical microscopy and FT-IR microspectroscopy for molecular composition identification, designed for various user skill levels.
- Preparations begin for Quantum BioPharma's planned Phase 2 multiple sclerosis drug trial
Quantum BioPharma initiated preparations for its Phase 2 Lucid-MS trial for multiple sclerosis, collaborating with Thermo Fisher Scientific for clinical research services.
- Exclusive: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Quantum BioPharma is collaborating with Thermo Fisher Scientific for a Phase 2 clinical trial of Lucid-MS, a multiple sclerosis drug targeting myelin breakdown.
- Thermo Fisher Stocks Rise as JPMorgan Adds October Favorite
Thermo Fisher Scientific's stock increased after JPMorgan added it to its October growth picks, following strong Q2 results with increased revenue and operating profit margins.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Thermo Fisher Scientific?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies